Targeting Inflammation in Atherosclerotic Disease - The New Frontier-Novel Therapies for Targeting Inflammation in ASCVD, Dr. Jennifer A. Rymer and Discussion

Novel Therapies for Targeting Inflammation in ASCVD, Dr. Jennifer A. Rymer and Discussion

Video Transcription

Video Summary

The discussion focused on advancements in cardiovascular therapies targeting inflammation, particularly highlighting ziltivecumab, a monoclonal antibody targeting IL-6. The speaker emphasized the potential benefits of targeting both acute and chronic inflammatory processes related to cardiovascular diseases like coronary artery disease and peripheral vascular disease. The Artemis trial was highlighted, aiming to assess ziltivecumab's efficacy in reducing Major Adverse Cardiovascular Events (MACE) and exploring its impact on inflammation in acute myocardial infarction patients. Concerns about inflammation reduction were raised, including the potential increased risks of infections and cancer. Colchicine, although often discussed for its adverse effects, was mentioned as potentially beneficial in chronic conditions like peripheral vascular disease. The session also briefly addressed the role of inflammatory markers like HSCRP and lipoprotein(a) in cardiovascular risk management, underscoring their value in current and future therapeutic strategies.

Keywords

ziltivecumab

cardiovascular inflammation

Artemis trial

Major Adverse Cardiovascular Events

HSCRP